A single-center, open-label, single-dose study investigating the safety, tolerability, and pharmacokinetic properties of nalmefene 10 mg tablets in healthy Japanese male subjects
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Nalmefene (Primary)
- Indications Alcoholism
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 25 Oct 2016 Status changed from active, no longer recruiting to completed.
- 08 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
- 08 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.